---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-020109"
form_type: "8-K"
ticker: null
cik: "0001358403"
company_name: "BELLICUM PHARMACEUTICALS, INC"
filed_at: "2023-05-30T23:59:59+00:00"
generated_at: "2026-06-14T11:24:55.188010+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Bellicum Pharmaceuticals receives delisting notice from Nasdaq; to trade on OTCQX

## Summary
- Nasdaq will suspend trading of BLCM common stock at open on June 2, 2023 due to non-compliance with equity continued listing rule.
- Company did not submit a compliance plan to Nasdaq as required by May 19, 2023.
- No appeal will be filed; common stock to trade on OTCQX marketplace under symbol BLCM.
- Previous disclosure indicated stockholders' equity failed Nasdaq's minimum requirement.

## SEC filing metadata
- accession: 0001628280-23-020109
- form_type: 8-K
- cik: 0001358403
- company_name: BELLICUM PHARMACEUTICALS, INC
- filed_at: 2023-05-30T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1358403/000162828023020109/0001628280-23-020109-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1358403/000162828023020109/blcm-20230530.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-020109
- JSON: https://secwatch.observer/filing/0001628280-23-020109.json
- Plain text: https://secwatch.observer/filing/0001628280-23-020109.txt

## Key facts
- Listing & Compliance Notices
  BELLICUM PHARMACEUTICALS, INC received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: May 24, 2023, the Company received written notification from Nasdaq stating that, subject to the Company’s right to request an appeal, trading of the Company’s common stock will be suspended at the opening of business on June 2, 2023, and a Form 25-NSE will be filed thereafter with the SEC, which will remove the Company’s securities from listing and registration on Nasdaq. The Company does not intend to request an appeal of the delisting determination. The Company anticipates that effective June 2, 2023, the Company’s common stock will commence trading on the OTCQX marketplace under the symbol
  evidence_url: https://www.sec.gov/Archives/edgar/data/1358403/000162828023020109/0001628280-23-020109-index.htm
- Listing & Compliance Notices
  BELLICUM PHARMACEUTICALS, INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: April 6, 2023, the Company received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s stockholders’ equity as reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 does not satisfy the Nasdaq Capital Market continued listing requirement set forth in Nasdaq Listing Rule 5550(b)(1) (“Rule 5550(b)(1)”). The Company was given until May 19, 2023 to submit to Nasdaq a plan to regain compliance with Rule 5550(b)(1). The Company did not submit such a plan to Nasdaq. As a result, on May 24, 2023, the Company received written notification from Nasd
  evidence_url: https://www.sec.gov/Archives/edgar/data/1358403/000162828023020109/0001628280-23-020109-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.